Stockscreener 앱 받기
4.70
0.86%
0.04
시간 외 거래:
4.72
0.02
+0.43%
전일 마감가:
$4.66
열려 있는:
$4.7
하루 거래량:
16,841
Relative Volume:
0.64
시가총액:
$6.19M
수익:
-
순이익/손실:
$-38.35M
주가수익비율:
-2.3383
EPS:
-2.01
순현금흐름:
$-36.91M
1주 성능:
-7.48%
1개월 성능:
-19.10%
6개월 성능:
-61.71%
1년 성능:
-69.17%
1일 변동 폭
$4.66
$4.86
1주일 범위
$4.4006
$5.415
52주 변동 폭
$4.4006
$23.50
Galecto Inc Stock (GLTO) Company Profile
명칭
Galecto Inc
전화
45-70-70-52-10
주소
75 STATE STREET, BOSTON
GLTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
4.70 | 6.19M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | BofA Securities | Buy |
| 2020-11-23 | 개시 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | SVB Leerink | Outperform |
Galecto Inc 주식(GLTO)의 최신 뉴스
Galecto stock plunges to 52-week low at $4.78 amid market challenges - Investing.com
Galecto stock hits 52-week low at $5.26 amid market challenges - Investing.com Nigeria
Galecto stock hits 52-week low at $5.26 amid market challenges By Investing.com - Investing.com South Africa
(GLTO) Trading Signals - Stock Traders Daily
Galecto stock hits 52-week low at $5.51 amid market challenges - Investing.com Australia
GLTO (Galecto) Momentum Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Report 2034, - openPR
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
GLTO (Galecto) EBITDA per Share : $-17.96 (TTM As of Sep. 2024) - GuruFocus.com
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
Galecto stock hits 52-week low at $6.46 amid market challenges - Investing.com India
Galecto Inc. (GLTO) Quarterly 10-Q Report - Quartzy
(GLTO) Investment Report - Stock Traders Daily
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN
Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN
Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN
Galecto Reports Third Quarter 2024 Financial Results - The Manila Times
(GLTO) On The My Stocks Page - Stock Traders Daily
Global Secondary Myelofibrosis Therapeutics Market Poised to Reach USD 2.74 Million by 2033 with a 6 - PharmiWeb.com
Galecto price target raised to $10 from $9 at Oppenheimer - Yahoo Finance
How to Take Advantage of moves in (GLTO) - Stock Traders Daily
Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer - MarketBeat
Galecto (NASDAQ:GLTO) Given New $10.00 Price Target at Oppenheimer - MarketBeat
Galecto adds Dr. Amy Wechsler to Board of Directors By Investing.com - Investing.com Canada
Galecto stock hits 52-week low at $6.61 amid market challenges - Investing.com Canada
Galecto adds Dr. Amy Wechsler to Board of Directors - Investing.com
Galecto Appoints Dr. Amy Wechsler to Board - TipRanks
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - The Manila Times
Galecto refocuses on cancer, acquires novel AML drug rights By Investing.com - Investing.com South Africa
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
Galecto stock hits 52-week low at $9.3 amid market challenges - Investing.com
Galecto stock hits 52-week low at $9.3 amid market challenges By Investing.com - Investing.com South Africa
Galecto Expands Oncology Portfolio with Strategic Acquisition - TipRanks
Galecto refocuses on cancer, acquires novel AML drug rights - Investing.com
Galecto Shares Slide on Leukemia Treatment Rights Acquisition - MarketWatch
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - The Manila Times
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
KBW Bank Index (BKX) QuotePress Release - The Globe and Mail
Charter Communications Inc (CHTR-Q) QuotePress Release - The Globe and Mail
Robusta Coffee 10-T (RMK26) Quote - The Globe and Mail
Galecto Inc (GLTO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):